
While Sanofil continues to triumph with eczema drug Dupixent, with Leo Pharma also working to launch its medicament, Adtralza, targeting the skin disease, both in the EU and US, Eli Lilly now moves closer to the finish line with its treatment candidate.
Eli Lilly informs that its drug candidate, lebrikizumab, rights for which were purchased from Dermira, has shown fine results in studies involving adults, children and youth aged between 12 and 18.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app